Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2009

Bayer Decides to Investigate Compugen’s Newly Discover Cancer Targets

  • Bayer Schering Pharma has inked a deal to evaluate a Compugen-discovered tumor target and its splice variants. Following an initial six-month joint research stage, the agreement provides Bayer with an option for an exclusive, worldwide, royalty-bearing license for development of mAbs and other therapeutic agents addressing these target molecules.

    The existence of the target and its splice variants was initially predicted in silico by Compugen through the use of its Monoclonal Antibody Targets Discovery platform. The newly discovered target and its splice variants are variants of a known cancer target for which therapeutic agents are currently in preclinical development by other organizations. Like the known cancer target, this protein molecule and its variants are all trans-membrane proteins. However, each of the Compugen molecules has a unique sequence at the extracellular domain of the protein that enables the development of mAbs specific to each of the respective splice variants.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »